Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer

Published:2022-02-28 Issue:2 Volume:5 Page:e2145460
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Dai Wei Fang¹²,Beca Jaclyn M.²³,Nagamuthu Chenthila⁴,Liu Ning⁴,de Oliveira Claire⁴⁵,Earle Craig C.⁴,Trudeau Maureen⁶,Mercer Rebecca E.²³,Chan Kelvin K. W.¹²³⁶

Affiliation:

1. Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

2. Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada

3. Ontario Health–Cancer Care Ontario, Ontario, Canada

4. ICES, Ontario, Canada

5. Centre for Health Economics and Hull York Medical School, York,

6. Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2789454/dai_2022_oi_211255_1645202384.41656.pdf

Reference30 articles.

1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.;Slamon;N Engl J Med,2001

2. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.;Baselga;N Engl J Med,2012

3. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.;Swain;N Engl J Med,2015

4. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.;Swain;Lancet Oncol,2020

5. Efficacy of pertuzumab in combination with trastuzumab and a taxane in first-line treatment for metastatic breast cancer (MBC): a multicenter, retrospective, observational study.;Gamucci;J Clin Oncol,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS);BMC Pharmacology and Toxicology;2023-11-13

2. Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records;JCO Oncology Practice;2023-07

3. Breast Cancer and Human Epidermal Growth Factor Receptor 2: Overexpression and Related Drugs;Highlights in Science, Engineering and Technology;2023-03-21

4. Use of real-world data for decision making in Canada and United Kingdom;Real-World Data & Evidence;2022-11-17

5. Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer;JAMA Oncology;2022-04-01